Skip to content
Screener

Glaukos GKOS Business Segments — Net Income Loss

Similar metrics at other companies

Nuvectis Pharma, Inc. logo
NVCTClinical Development — Net Income Loss
-$6.05M-13.5%
Amplitech Group, Inc. logo
AMPGManufacturing And Engineering — Net Income Loss
-$448.94K+71.6%
WesBanco logo
WSBCCorporate And Other — Net Income Loss
-$5.8M+46.7%
Duos Technologies Group, Inc. logo
DUOTCorporate And Unallocated — Net Income Loss
-$1.23M-26.6%
EMP
EMPDCorporate And Other — Net Income Loss
-$83.38M
Dominion Energy logo
DCorporate And Other — Net Income Loss
-$294M-87.3%

Other financials

Income statement

See full
Revenue$185.6M+49.5%
Gross profit$151.6M+55.9%
Operating income-$17.3M+23.9%
Net income-$18.4M+6.5%
EPS (diluted)-$0.31+8.8%

Balance sheet

See full
Cash & equivalents$114.5M+13.6%
Total debt$105.9M-1.4%
Total equity$682.5M-10.8%
Total assets$920.5M-6.7%

Cash flow

See full
Operating cash flow$14.8M
CapEx$2.7M+132%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$10.08B+98.7%
Enterprise value$10.07B+98.2%
P/S16.5×+4.7×

Profitability

See full
Gross margin61%-15.4pp
Operating margin-31.6%+22.2pp
Net margin-30.7%+23.3pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26%-11,301pp
Debt / equity0.2×0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Glaukos’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324201
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Interest expense(1,459)(1,151)(2,584)(2,314)
Other (expense) income, net(1,274)1,857(2,023)2,802
Total non-operating (expense) income(454)3,2801036,138
Loss before taxes(17,721)(19,409)(37,020)(37,229)
Income tax provision6562481,140574
Net loss$(18,377)$(19,657)$(38,160)$(37,803)
Basic and diluted net loss per share$(0.31)$(0.34)$(0.65)$(0.66)
Weighted-average shares outstanding used to compute basic and diluted net loss per share58,81857,20558,41956,922

Item 1. Financial Statements

FAQ

What is Glaukos's business segments — net income loss?
Glaukos (GKOS) reported business segments — net income loss of -$18.38M in Q2 2026.
How has Glaukos's business segments — net income loss changed year-over-year?
Glaukos's business segments — net income loss increased by 6.5% year-over-year, from -$19.66M to -$18.38M.
What is the long-term trend for Glaukos's business segments — net income loss?
Over 3 years (2022 to 2025), Glaukos's business segments — net income loss has grown at a 23.7% compound annual growth rate (CAGR), from -$99.2M to -$187.69M.
What does business segments — net income loss mean?
This is the bottom-line financial result for the ophthalmic therapies segment, calculated as total segment revenue minus all associated operating expenses, taxes, and non-operating costs. It serves as the primary indicator of the segment's standalone economic viability and contribution to the overall corporate bottom line.

Ask your AI about Glaukos's business segments — net income loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude